Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women (LIVIIN)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by University of Pittsburgh.
Recruitment status was:  Active, not recruiting
Society of Family Planning
Information provided by (Responsible Party):
University of Pittsburgh Identifier:
First received: February 13, 2012
Last updated: May 22, 2013
Last verified: May 2013

February 13, 2012
May 22, 2013
June 2012
May 2013   (final data collection date for primary outcome measure)
To assess change in pain from baseline to IUD insertion as determined by 100mm visual analog scale (VAS) for self-administered intravaginal 2% lidocaine gel as compared to placebo gel. [ Time Frame: One year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01534520 on Archive Site
  • To evaluate patient acceptability of self-inserting the intravaginal study gel prior to IUD [ Time Frame: One year ] [ Designated as safety issue: No ]
  • To measure ease of IUD insertion as reported by physicians [ Time Frame: One year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women
Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial
This study is designed to evaluate if self-inserted intravaginal 2% lidocaine gel is effective at decreasing pain during intrauterine device insertion in nulliparous women.

Intrauterine devices (IUDs) are among the most effective forms of reversible contraception. Numerous studies demonstrate their safety and efficacy in nulliparous women, however, uptake of IUDs in this group is low. One of the major barriers to women obtaining IUDs is fear of pain during insertion, as studies do demonstrate that nulliparous women experience more pain than parous women during IUD insertion. Studies evaluating various methods for pain control during IUD insertion have shown conflicting results, leaving the question unanswered as to what is the best method to decrease pain during IUD insertion.

This study aims to evaluate a novel approach to pain control by having women self-insert lidocaine gel into the vagina at least 5 minutes prior to IUD insertion. This will overcome some of the barriers from other studies where there may not have been ample time for the lidocaine to take effect, while at the same time eliminating the need for women to have multiple speculum exams. Although this is a novel approach to administering an anesthetic, we believe women will be interested in any intervention that may potentially alleviate pain during IUD insertion.

If this study does demonstrate that pain is decreased with self-inserted lidocaine compared to placebo gel, this will potentially eliminate one large barrier to nulliparous women receiving IUDs. Increased uptake of highly effective contraception in nulliparous women is just one of the many steps necessary towards decreasing unintended pregnancy.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Drug: Lidocaine
    Intravaginal insertion of 5mL 2% lidocaine gel
    Other Names:
    • Lidocaine Jelly
    • Lidocaine Hydrochloride
  • Drug: Placebo
    KY Jelly
  • Placebo Comparator: Placebo
    Intravaginal insertion of 5mL placebo gel
    Intervention: Drug: Placebo
  • Experimental: Study Drug
    Intravaginal insertion of 5mL 2% lidocaine gel
    Intervention: Drug: Lidocaine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Nulliparous, as defined in this study as no history of pregnancy ≥ 24 weeks gestational age
  • Desires insertion of either levonorgestrel-releasing IUD (LNG-IUD) or copper T380A IUD (Cu-IUD)
  • No history of pregnancy in the last 6 weeks
  • Able to provide written informed consent in English and comply with all study procedures

Exclusion criteria:

  • Known allergy or hypersensitivity to lidocaine or other amino amide local anesthetics
  • Prior failed IUD insertion
  • Prior IUD use
  • Use of narcotic or benzodiazepine medication within the last 24 hours
  • U.S. Centers for Disease Control Medical Eligibility Criteria (MEC) category 3 or 4 classification for use of an IUD
  • Positive pregnancy test or reasonable risk of pregnancy due to unprotected heterosexual intercourse since the last menstrual period
14 Years to 55 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
University of Pittsburgh
University of Pittsburgh
Society of Family Planning
Principal Investigator: Rachel B Rapkin, MD University of Pittsburgh
University of Pittsburgh
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP